Wealthfront Advisers LLC decreased its position in CVS Health Corporation (NYSE:CVS – Free Report) by 14.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 181,517 shares of the pharmacy operator’s stock after selling 30,784 shares during the quarter. Wealthfront Advisers LLC’s holdings in CVS Health were worth $13,037,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the company. TOWER TRUST & INVESTMENT Co raised its holdings in shares of CVS Health by 0.8% in the 4th quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock valued at $1,247,000 after buying an additional 132 shares during the period. CYBER HORNET ETFs LLC boosted its holdings in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock valued at $259,000 after acquiring an additional 134 shares during the period. LS Investment Advisors LLC grew its position in CVS Health by 3.9% in the 4th quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after acquiring an additional 135 shares in the last quarter. Moss Adams Wealth Advisors LLC increased its stake in CVS Health by 4.7% during the fourth quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after purchasing an additional 135 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC increased its stake in CVS Health by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock worth $3,219,000 after purchasing an additional 136 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the stock. Bank of America raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, June 22nd. Robert W. Baird upped their target price on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 15th. HSBC reiterated a “hold” rating and set a $103.00 target price on shares of CVS Health in a report on Monday, July 6th. UBS Group boosted their price target on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday, June 8th. Finally, DA Davidson upped their price objective on CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $105.38.
Insider Buying and Selling at CVS Health
In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the sale, the executive vice president directly owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Corporate insiders own 0.85% of the company’s stock.
CVS Health Stock Performance
Shares of CVS Health stock opened at $106.51 on Friday. The business has a 50-day simple moving average of $98.64 and a 200-day simple moving average of $84.98. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. CVS Health Corporation has a one year low of $58.50 and a one year high of $108.67. The company has a market cap of $135.90 billion, a PE ratio of 46.92, a P/E/G ratio of 1.03 and a beta of 0.61.
CVS Health (NYSE:CVS – Get Free Report) last issued its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. During the same quarter last year, the company earned $2.25 earnings per share. The firm’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities research analysts forecast that CVS Health Corporation will post 7.46 EPS for the current fiscal year.
CVS Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is presently 117.18%.
Key CVS Health News
Here are the key news stories impacting CVS Health this week:
- Positive Sentiment: CVS is benefiting from a sector-wide lift after UnitedHealth delivered a large earnings beat and raised guidance, which helped improve sentiment across managed-care stocks including CVS. UNH Stock Flashes Buy Signal On Massive Earnings Beat
- Positive Sentiment: Truist reportedly reiterated a bullish stance with a new $118 price target, reinforcing the view that CVS still has room to run after recently hitting fresh highs. CVS Health Given New $118.00 Price Target at Truist Financial
- Positive Sentiment: CVS also continues to draw favorable analyst attention, with reports highlighting optimistic Wall Street recommendations and broader confidence in the stock’s fundamentals. Is CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic?
- Neutral Sentiment: Aetna’s provider survey showed improved payer trust and interest in digital tools, which is constructive for CVS Health’s Aetna segment but not likely a near-term stock mover. Aetna provider survey reveals increased payer trust and tangible benefits of digital tools to improve patient outcomes
- Negative Sentiment: Regulatory scrutiny remains a key overhang after reports that CVS Caremark reached a settlement with the FTC over rebate practices, pharmacy access, and transparency, which could pressure margins or invite more oversight. FTC Says CVS Caremark Settlement Could Save Consumers Upto $13 Billion
- Negative Sentiment: Some commentary also suggests CVS may be trading at a demanding valuation after its recent run, which could limit upside if earnings growth does not keep pace. The Real Price of Admission for CVS Health Stock
CVS Health Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
See Also
- Five stocks we like better than CVS Health
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
